ST. LOUIS -- A pilot study at Saint Louis University Center for
Vaccine Development could shape the future of tuberculosis
vaccine research by developing tests to identify the most
promising vaccine candidates to address this global health
crisis. |Daniel Hoft, M.D., Ph.D., will use sophisticated
equipment to detect changes in the body's response to
infection.| "Our goal is to save lives faster," said Daniel
Hoft, M.D., Ph.D., director of the division of infectious
diseases, allergy and immunology at SLU. "We hope to develop a
process that will allow us to screen new TB vaccines for
inducing immunity in people, which will get us on the right
research track faster and save valuable research dollars." It's
critical to find a vaccine to protect people from tuberculosis,
which the World Health Organization has declared a global health
emergency. The Mycobacterium tuberculosis pathogen that causes
TB is one of the world's deadliest infectious agents, costing an
estimated two million lives a year. Further, treating